MPO and neoplasm: The pharmacological inhibition of the myeloperoxidase pathway in PMN-MDSCs restored DC cross-presentation, suggesting that drugs targeting the myeloperoxidase pathway have the potential to restore DC cross-presentation and enhance anti-tumor immune responses.